Protocol Ledger

NCT07604766 · Phase III · RECRUITING

An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China

Interventional Phase III clinical trial protocol NCT07604766 sponsored by Genmab in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-06-26 Enrollment: 82 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07604766
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)82 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07604766
Protocol FieldVerified Registry Value
NCT IdentifierNCT07604766
Consolidated Lead SponsorGenmab
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment82 participants (ESTIMATED)
Registered Start Date2026-06-26
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07604766
Hospital Research SiteLocationSite Profile
The First Hospital of Jilin UniversityChangchun, ChinaOpen Hospital Dossier ->
Hunan Cancer HospitalChangsha, ChinaOpen Hospital Dossier ->
Sun Yat-sen Memorial HospitalGuangzhou, ChinaOpen Hospital Dossier ->
Sun Yat-sen University Cancer CenterGuangzhou, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI